Veröffentlichungen

Small molecule specifically inhibiting microglial nitric oxide release could become a potential treatment for neuroinflammation

P. Jordan
A. Costa
E. Specker
O. Popp
A. Volkamer
R. Piske
T. Obrusnik
S. Kleissle
K. Stuke
A. Rex
M. Neuenschwander
J.P. von Kries
M. Nazare
P. Mertins
H. Kettenmann
S.A. Wolf

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod

L. Starke
J.M. Millward
C. Prinz
F. Sherazi
H. Waiczies
C. Lippert
M. Nazaré
F. Paul
T. Niendorf
S. Waiczies

Development of selective inhibitors of phosphatidylinositol 3-kinase C2α

W.T. Lo
H. Belabed
M. Kücükdisli
J. Metag
Y. Roske
P. Prokofeva
Y. Ohashi
A. Horatscheck
D. Cirillo
M. Krauss
C. Schmied
M. Neuenschwander
J.P. von Kries
G. Médard
Be. Kuster
O. Perisic
R.L. Williams
O. Daumke
B. Payrastre
S. Severin
M. Nazaré
V. Haucke

06. Dezember 2022 / Circulation

Mutant phosphodiesterase 3A protects from hypertension-induced cardiac damage

M. Ercu
M.B. Mücke
T. Pallien
L. Markó
A. Sholokh
C. Schächterle
A. Aydin
A. Kidd
S. Walter
Y. Esmati
B.J. McMurray
D.F. Lato
D.Y. Sunaga-Franze
P.H. Dierks
B.I.M. Flores
R. Walker-Gray
M. Gong
C. Merticariu
K. Zühlke
M. Russwurm
T. Liu
T.U.P. Batolomaeus
S. Pautz
S. Schelenz
M. Taube
H. Napieczynska
A. Heuser
J. Eichhorst
M. Lehmann
D.C. Miller
S. Diecke
F. Qadri
E. Popova
R. Langanki
M.A. Movsesian
F.W. Herberg
S.K. Forslund
D.N. Müller
T. Borodina
P.G. Maass
S. Bähring
N. Hübner
M. Bader
E. Klussmann

Compound interaction screen on a photoactivatable cellulose membrane (CISCM) identifies drug targets

F.T. Melder
P. Lindemann
A. Welle
V. Trouillet
S. Heißler
M. Nazaré
M. Selbach

Structure-based design of xanthine-benzimidazole derivatives as novel and potent tryptophan hydroxylase inhibitors

E. Specker
S. Matthes
R. Wesolowski
A. Schütz
M. Grohmann
N. Alenina
D. Pleimes
K. Mallow
M. Neuenschwander
A. Gogolin
M. Weise
J. Pfeifer
N. Ziebart
U. Heinemann
J.P. von Kries
M. Nazaré
M. Bader

Phosphoinositide conversion inactivates R-RAS and drives metastases in breast cancer

H. Li
L. Prever
M.Y. Hsu
W.T. Lo
J.P. Margaria
M.C. De Santis
C. Zanini
M. Forni
F. Novelli
S. Pece
P.P. Di Fiore
P.E. Porporato
M. Martini
H. Belabed
M. Nazare
V. Haucke
F. Gulluni
E. Hirsch

Rational design of highly potent, selective, and bioavailable SGK1 protein kinase inhibitors for the treatment of osteoarthritis

N. Halland
F. Schmidt
T. Weiss
Z. Li
J. Czech
J. Saas
D. Ding-Pfennigdorff
M.K. Dreyer
C. Strübing
M. Nazare

Development of a 1,2,4-triazole-based lead tankyrase inhibitor: part II

R.G.G. Leenders
S.A. Brinch
S.T. Sowa
E. Amundsen-Isaksen
A. Galera-Prat
S. Murthy
S. Aertssen
J.N. Smits
P. Nieczypor
E. Damen
A. Wegert
M. Nazaré
L. Lehtiö
J. Waaler
S. Krauss

Pentafluorosulfanyl (SF(5)) as a superior (19)F magnetic resonance reporter group: signal detection and biological activity of teriflunomide derivatives

C. Prinz
L. Starke
T.F. Ramspoth
J. Kerkering
V. Martos Riaño
J. Paul
M. Neuenschwander
A. Oder
S. Radetzki
S. Adelhoefer
P. Ramos Delgado
M. Aravina
J.M. Millward
A. Fillmer
F. Paul
V. Siffrin
J.P. von Kries
T. Niendorf
M. Nazaré
S. Waiczies